| Market Capitalization (Millions $) |
132 |
| Shares
Outstanding (Millions) |
72 |
| Employees |
41 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-16 |
| Cash Flow (TTM) (Millions $) |
-21 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Biomea Fusion Inc is a public pharmaceutical company that focuses on the development and commercialization of transformative therapies for patients with genetically defined cancers. The company was founded in 2013 in Emeryville, California, by Dr. Sandesh Seth, a leading oncologist and biotech executive.
The mission of Biomea Fusion is to harness the power of genomic science to develop precision medicine treatments for patients with cancer. The company has a proprietary drug discovery platform that integrates advanced genomic analytics, bioinformatics, and synthetic biology to identify novel targets and develop therapies that can overcome the limitations of existing treatments.
Biomea Fusion's pipeline includes several innovative drug candidates in development for various cancers, including solid tumors and hematologic malignancies. One of its leading candidates is BMF-219, a selective inhibitor of the fusion protein FGFR3-TACC3, which is being developed for patients with bladder cancer and other solid tumors.
The company is also developing BMF-236, an oral FLT3/AXL dual inhibitor, for the treatment of acute myeloid leukemia (AML) and other hematologic malignancies. Biomea Fusion's third clinical-stage asset is BMF-140, a targeted therapy for patients with solid tumors harboring NRG1 gene fusions.
In addition to its clinical programs, Biomea Fusion is actively pursuing preclinical and research activities to develop additional drug candidates for patients with cancer.
The company has a strong leadership team and board of directors with extensive experience in both biotech and pharmaceutical industries. Biomea Fusion has received multiple rounds of funding from venture capital firms and listed on the NASDAQ stock exchange in February 202 With a focus on precision medicine and genomic science, Biomea Fusion is at the forefront of developing transformative therapies for patients with cancer.
Company Address: 1599 Industrial Road San Carlos 94070 CA
Company Phone Number: 980-9099 Stock Exchange / Ticker: NASDAQ BMEA
|
0.86%